At BioROSA Technologies, we want to make the diagnosis of autism spectrum disorders (ASD) rapid and simple. We looked to the diagnostic industry standard, a blood draw, for the answer. From blood, we measure metabolic biomarkers to obtain a signal, and then we use machine learning to process that signal into a reliable and accurate diagnosis. Currently our first-in-class solution can differentiate whether a blood sample came from a child with ASD or not with 95% sensitivity and 92% specificity based on metabolic profiles derived from mass spectrometry analytical methods combined with machine learning.
There is no broad-based molecular diagnostic test for clinicians to assess ASD risk on the market today.
The average age of ASD diagnosis is 4 years old. Parents suspect problems as early as 12 months.
Autism is estimated to effect anywhere between 1/40 to 1/59 children in the United States and up to 2.5% of children worldwide (CDC, 2017; Pediatrics, 2018)
Autism costs society up to $230B per year
Co-founder & CEO
John Slattery spent over 7 years conducting clinical trials in ASD and has over 35 highly cited peer reviewed articles, one book chapter, and editorials related to the metabolic basis of ASD. John has also been actively involved in the startup and entrepreneurial communities and is considered a thought leader and expert in integrated systems biology in complex disease with a focus on precision medicine strategies to improve patient outcomes, specifically for neuropsychiatric and neurodevelopmental disorders.
Co-founder & CSO
Marie Causey received her PhD from Albert Einstein and did a post-doc at Harvard in molecular genetics. Marie has over 10 years experience in establishing CLIA labs and developing laboratory developed tests (LDTs). Marie is a diagnostics industry veteran and has been a founder or senior scientist in multiple startup companies. Notably, in relation to ASD, Marie was a co-founder with Stan Lapidus in SynapDx.